Genexine, Inc.: Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced

Related Keywords

Seoul ,Soult Ukpyolsi ,South Korea ,United States ,Paris ,France General ,France ,Korea ,Edward Shin ,Kostenloser Wertpapierhandel ,Jongsoo Lee ,European Society For Medical Oncology Congress ,Genexine Inc ,Korean Financial Supervisory Service ,Merck Co Inc ,Merck Sharp Dohme ,Ministry Of Food ,National Cancer Drug Development Project Of Korea ,Medical Oncology Congress ,Oral Session ,Neil Warma Genexine ,Drug Safety ,Growth Hormone Deficiency ,National Cancer Drug Development Project ,Human Papillomavirus ,Data Analysis ,Transfer System ,Korean Financial Supervisory ,Investor Relations ,Genexine ,Elected ,Gate ,Breaking ,Mural ,Presentation ,Hase ,Study ,88e ,Combination ,Keytruda ,Pembrolizumab ,Cervical ,Dancer ,European ,Society ,Medical ,Ncology ,Osmo ,Congress ,022 ,